Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.
TG Therapeutics
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Kesimpta: Highly Effective New Drug for Multiple Sclerosis
Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.